Corgard

(Nadolol)

ApprovedSmall molecule

UUSWM, LLC (dba US WorldMeds)

Corgard is one of 100 small molecule programs targeting Hemangioma. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

HemangiomaActive, not recruiting

AsthmaActive, not recruiting

CirrhosisActive, not recruiting

Smoking CessationActive, not recruiting

HemangiomaPhase 2

Active, not recruiting

AsthmaPhase 2

Active, not recruiting

CirrhosisApproved

Active, not recruiting

Smoking CessationPhase 2

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Corgard

UUSWM, LLC (dba US WorldMeds)

Approved

2 2

Veramyst

GSK

Preclinical

46 3

Singulair

AstraZeneca

Preclinical

17 4

Cinqair

Teva

Preclinical

13 5

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

30 6

Asmanex

Novartis

Preclinical

5 7

Celexa

AbbVie

Preclinical

1 8

Spiriva

Boehringer Ingelheim

Preclinical

8 9

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

8 10

Atrovent

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Adjuvant

NCT06643221

Clinical

Trials by Indication[1]

Asthma2 trials

Oral Nadolol for the Treatment of Adults With Mild Asthma

Completed·IInvion, Inc.·Phase 1/2·NCT00670267·10 enrolled

Efficacy and Safety of Beta-adrenoceptor Inverse Agonist, Nadolol, in Mild Asthma

Unknown status·IInvion, Inc.·Phase 2·NCT01804218·60 enrolled

Hemangioma2 trials

Nadolol Versus Propranolol in Children With Infantile Hemangiomas

Completed·TThe Hospital for Sick Children·Phase 3·NCT02505971·74 enrolled

Nadolol for Proliferating Infantile Hemangiomas

Completed·TThe Hospital for Sick Children·Phase 2·NCT01010308·20 enrolled

Prophylaxis1 trial

Secondary Prophylaxis After Variceal Bleeding in Non-Responders

Completed·FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau·Phase 4·NCT00450164·50 enrolled

Smoking Cessation1 trial

Efficacy and Safety of Βeta-adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, In Smoking Cessation of Patients With Chronic Cough With or Without Airflow Obstruction

Completed·IInvion, Inc.·Phase 2·NCT01825122·155 enrolled

Cirrhosis1 trial

A Trial of Ligation Plus Nadolol Versus Nadolol Alone in the Prophylaxis of First Variceal Bleeding in Cirrhosis

Completed·NNational Science and Technology Council, Taiwan·Phase 4·NCT00921349·140 enrolled

3 more indications

Adjuvant1 trial

Exercise as an Immune Adjuvant for Allogeneic Cell Therapies

Recruiting·UUniversity of Arizona·Phase 1·NCT06643221·100 enrolled

Fasting Conditions1 trial

Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions

Completed· Novartis logo

Novartis·Phase 1·NCT00960245·34 enrolled

Prevention1 trial

Endoscopic Cyanoacrylate Obliteration vs. Nadolol Treatment in the Prevention of Gastric Variceal Rebleeding

Unknown status·TTaipei Veterans General Hospital, Taiwan·Phase 4·NCT00567216·120 enrolled

Regulatory

FDA Approval Timeline[4]

Oct 28, 1986

CORGARD

NDA NDA018063

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Nadolol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nadolol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nadolol. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA018063). U.S. Food & Drug Administration.
[5]
SEC EDGAR — USWM, LLC (dba US WorldMeds) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUSWM, LLC (dba US WorldMeds)

Corgard

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Asthma2 trials

Hemangioma2 trials

Prophylaxis1 trial

Smoking Cessation1 trial

Cirrhosis1 trial

Adjuvant1 trial

Fasting Conditions1 trial

Prevention1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News